Publication:
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis

dc.contributor.authorSuthar, Amitabh B
dc.contributor.authorLawn, Stephen D
dc.contributor.authorAmo, Julia del
dc.contributor.authorGetahun, Haileyesus
dc.contributor.authorDye, Christopher
dc.contributor.authorSculier, Delphine
dc.contributor.authorSterling, Timothy R
dc.contributor.authorChaisson, Richard E
dc.contributor.authorWilliams, Brian G
dc.contributor.authorHarries, Anthony D
dc.contributor.authorGranich, Reuben M
dc.date.accessioned2018-11-20T12:21:22Z
dc.date.available2018-11-20T12:21:22Z
dc.date.issued2012-07-24
dc.description.abstractBACKGROUND: Human immunodeficiency virus (HIV) infection is the strongest risk factor for developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In 2010, there were an estimated 1.1 million incident cases of tuberculosis among the 34 million people living with HIV worldwide. Antiretroviral therapy has substantial potential to prevent HIV-associated tuberculosis. We conducted a systematic review of studies that analysed the impact of antiretroviral therapy on the incidence of tuberculosis in adults with HIV infection. METHODS AND FINDINGS: PubMed, Embase, African Index Medicus, LILACS, and clinical trial registries were systematically searched. Randomised controlled trials, prospective cohort studies, and retrospective cohort studies were included if they compared tuberculosis incidence by antiretroviral therapy status in HIV-infected adults for a median of over 6 mo in developing countries. For the meta-analyses there were four categories based on CD4 counts at antiretroviral therapy initiation: (1) less than 200 cells/µl, (2) 200 to 350 cells/µl, (3) greater than 350 cells/µl, and (4) any CD4 count. Eleven studies met the inclusion criteria. Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis in all baseline CD4 count categories: (1) less than 200 cells/µl (hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.07 to 0.36), (2) 200 to 350 cells/µl (HR 0.34, 95% CI 0.19 to 0.60), (3) greater than 350 cells/µl (HR 0.43, 95% CI 0.30 to 0.63), and (4) any CD4 count (HR 0.35, 95% CI 0.28 to 0.44). There was no evidence of hazard ratio modification with respect to baseline CD4 count category (p = 0.20). CONCLUSIONS: Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis across all CD4 count strata. Earlier initiation of antiretroviral therapy may be a key component of global and national strategies to control the HIV-associated tuberculosis syndemic. REVIEW REGISTRATION: International Prospective Register of Systematic Reviews CRD42011001209 Please see later in the article for the Editors' Summary.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThe authors were personally salaried by their institutions during the period of writing. No specific funding was received for this study. No funding bodies had any role in the study design, data collection, data analysis, decision to publish, or preparation of the manuscript.es_ES
dc.format.number7es_ES
dc.format.pagee1001270es_ES
dc.format.volume9es_ES
dc.identifier.citationPLoS Med. 2012;9(7):e1001270es_ES
dc.identifier.doi10.1371/journal.pmed.1001270es_ES
dc.identifier.e-issn1549-1676es_ES
dc.identifier.issn1549-1676es_ES
dc.identifier.journalPLoS medicinees_ES
dc.identifier.pubmedID22911011es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6640
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS)es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pmed.1001270es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdultes_ES
dc.subject.meshAnti-HIV Agentses_ES
dc.subject.meshCD4 Lymphocyte Countes_ES
dc.subject.meshHIV Infectionses_ES
dc.subject.meshHumanses_ES
dc.subject.meshQuality Assurance, Health Carees_ES
dc.subject.meshRandomized Controlled Trials as Topices_ES
dc.subject.meshTuberculosises_ES
dc.subject.meshAntiretroviral Therapy, Highly Activees_ES
dc.titleAntiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysises_ES
dc.typereview articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication0b34332e-721f-4cfb-9074-90822ef72868
relation.isAuthorOfPublication.latestForDiscovery0b34332e-721f-4cfb-9074-90822ef72868

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
AntiretroviralTherapyForPrevention_2012.pdf
Size:
395.82 KB
Format:
Adobe Portable Document Format
Description: